CDT (Conduit Pharmaceuticals) EPS (Basic) : $-0.19 (TTM As of Sep. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Conduit Pharmaceuticals EPS (Basic)?

Conduit Pharmaceuticals's basic earnings per share (Basic EPS) for the three months ended in Sep. 2024 was $-0.07. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Sep. 2024 was $-0.19.

Conduit Pharmaceuticals's EPS (Diluted) for the three months ended in Sep. 2024 was $-0.07. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was $-0.22.

Conduit Pharmaceuticals's EPS without NRI for the three months ended in Sep. 2024 was $-0.07. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Sep. 2024 was -0.25.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

Conduit Pharmaceuticals EPS (Basic) Historical Data

The historical data trend for Conduit Pharmaceuticals's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Conduit Pharmaceuticals EPS (Basic) Chart

Conduit Pharmaceuticals Annual Data

Trend

Dec21

Dec22

Dec23

EPS (Basic)

-0.05

-0.07

-0.01

Conduit Pharmaceuticals Quarterly Data
	Dec21	Mar22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
EPS (Basic)	Get a 7-Day Free Trial						0.04	-	-0.05	-0.07	-0.07

Conduit Pharmaceuticals EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Conduit Pharmaceuticals's Basic EPS for the fiscal year that ended in Dec. 2023 is calculated as

Basic EPS (A: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-0.535	-	0)	/	66.974
	=	-0.01

Conduit Pharmaceuticals's Basic EPS for the quarter that ended in Sep. 2024 is calculated as

Basic EPS (Q: Sep. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-6.461	-	0)	/	87.155
	=	-0.07

EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.19

Conduit Pharmaceuticals (NAS:CDT) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Conduit Pharmaceuticals EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Conduit Pharmaceuticals's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

Conduit Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Conduit Pharmaceuticals Inc (NAS:CDT) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

ZK7:Germany

Address

4995 Murphy Canyon Road, Suite 300, San Diega, CA, USA, 92123

Website

https://www.conduitpharma.com

Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being, prioritized by leading biopharmaceutical companies in order to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready in autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.

Executives

Andrew Regan	director, 10 percent owner	LE MANOIR DE LURIN, SAINT BARTHELEMY Z0 97133
Intelmed Llc	other: See Responses	11421 GOLDEN EAGLE COURT, NAPLES FL 34120
Jennifer Isacoff Mcnealey	director	C/O CODEX DNA, INC., 9535 WAPLES STREET, SUITE 100, SAN DIEGO Z4 92121
David Tapolczay	director, officer: Chief Executive Officer	32 CROUCH HALL LANE, ST. ALBANS X0 AL3 7EU
Faith L. Charles	director	ABEONA THERAPEUTICS INC., 1330 AVENUE OF THE AMERICAS - FLOOR 33, NEW YORK NY 10019
Algo Holdings, Inc.	10 percent owner, other: See Responses	100 W. CYPRESS CREEK ROAD, STE. 640, FORT LAUDERDALE NY 33309
Corvus Capital Ltd.	10 percent owner, other: See Responses	WILLOW HOUSE, CRICKET SQUARE PO BOX 709, GRAND CAYMAN E9 KY1 - 1107
Freda C Lewis-hall	director	C/O VERTEX PHARMACEUTICALS INCORPORATED, 130 WAVERLY STREET, CAMBRIDGE MA 02139
James Bligh	director	38 OXBERRY AVENUE, LONDON X0 SW6 5SS
Shaolin Capital Management Llc	10 percent owner	230 NW 24TH STREET, SUITE 603, MIAMI FL 33127
Richard Edward Feinberg	director	2855 FIFTH AVENUE, UNIT 405, SAN DIEGO CA 92103
Murphy Canyon Acquisition Sponsor, Llc	10 percent owner	4995 MURPHY CANYON ROAD, SUITE 300, SAN DIEGO CA 92123
Chele Chiavacci Farley	director	4 RIDGE ROAD, TUXEDO PARK NY 10987
Bentzen Edwin H Iv	officer: Chief Accounting Officer	2513 BIRCH HOLLOW ST, HENDERSON NV 89044
Jack Kendrick Heilbron	director, officer: CEO, President, and Chairman	16433 BRONCO LANE, POWAY CA 92064